Also from this source

You just read:

Trovagene Presents Data Showing Sensitivity of Triple Negative Breast Cancer (TNBC) Cell Lines to PCM-075 and Synergy with Zytiga® at San Antonio Breast Cancer Symposium (SABCS)

News provided by

Trovagene, Inc.

Dec 07, 2017, 16:00 EST